Updates are available Correction dated 2022-09-23
Click to view Correction: https://doi.org/10.1038/s41467-022-33355-0
-
Authors
Poels, Kamrine E. http://orcid.org/0000-0002-7220-2213
Schoenfeld, Adam J.
Makhnin, Alex
Tobi, Yosef http://orcid.org/0000-0003-0781-7681
Wang, Yuli
Frisco-Cabanos, Heidie
Chakrabarti, Shaon
Shi, Manli
Napoli, Chelsi
McDonald, Thomas O.
Tan, Weiwei
Hata, Aaron
Weinrich, Scott L.
Yu, Helena A.
Michor, Franziska http://orcid.org/0000-0003-4869-8842
-
Funding
Funding for this research was provided by:
Center for Strategic Scientific Initiatives, National Cancer Institute (U54CA193461)
- License Information
-
More Information
Article History
Received: 29 September 2020
Accepted: 24 May 2021
First Online: 17 June 2021
Change Date: 23 September 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-022-33355-0
Competing interests
: Y.W., W.T., M.S., and S.L.W. are employees of Pfizer and own stock in Pfizer. A.H. has received research funding from Pfizer, Novartis, Amgen, Roche/Genentech, Blueprint Medicines, Relay Therapeutics, and Eli Lilly. H.A.Y. has received research funding to her institution from Pfizer, Novartis, AstraZeneca, Cullinan, Lilly, Daichi. The remaining authors declare no competing interests. The scope of contributions by the Pfizer authors was specifically on preclinical components and did not involve clinical aspects of the work.
